key: cord-0334700-3ms1i4u0
authors: Srinivasan, Vasundara; Brognaro, Hévila; Prabhu, Prince R.; de Souza, Edmarcia Elisa; Günther, Sebastian; Reinke, Patrick Y. A.; Lane, Thomas J.; Ginn, Helen; Han, Huijong; Ewert, Wiebke; Sprenger, Janina; Koua, Faisal H. M.; Falke, Sven; Werner, Nadine; Andaleeb, Hina; Ullah, Najeeb; Franca, Bruno Alves; Wang, Mengying; Barra, Angélica Luana C; Perbandt, Markus; Schwinzer, Martin; Schmidt, Christina; Brings, Lea; Lorenzen, Kristina; Schubert, Robin; Guaragna Machado, Rafael Rahal; Candido, Erika Donizette; Leal Oliveira, Danielle Bruna; Durigon, Edison Luiz; Yefanov, Oleksandr; Lieske, Julia; Gelisio, Luca; Domaracky, Martin; Middendorf, Philipp; Groessler, Michael; Trost, Fabian; Galchenkova, Marina; Saouane, Sofiane; Hakanpää, Johanna; Wolf, Markus; Turk, Dusan; Pearson, Arwen R.; Chapman, Henry N.; Hinrichs, Winfried; Wrenger, Carsten; Meents, Alke; Betzel, Christian
title: SARS-CoV-2 papain-like protease PLpro in complex with natural compounds reveal allosteric sites for antiviral drug design
date: 2021-11-22
journal: bioRxiv
DOI: 10.1101/2021.11.17.468943
sha: e4118e139c3740e6a727cfc0bad5519510ccd2e1
doc_id: 334700
cord_uid: 3ms1i4u0

SARS-CoV-2 papain-like protease (PLpro) covers multiple functions. Beside the cysteine-protease activity, PLpro has the additional and vital function of removing ubiquitin and ISG15 (Interferon-stimulated gene 15) from host-cell proteins to aid coronaviruses in evading the host’s innate immune responses. We established a high-throughput X-ray screening to identify inhibitors by elucidating the native PLpro structure refined to 1.42 Å and performing co-crystallization utilizing a diverse library of selected natural compounds. We identified three phenolic compounds as potential inhibitors. Crystal structures of PLpro inhibitor complexes, obtained to resolutions between 1.7-1.9 Å, show that all three compounds bind at the ISG15/Ub-S2 allosteric binding site, preventing the essential ISG15-PLpro molecular interactions. All compounds demonstrate clear inhibition in a deISGylation assay, two exhibit distinct antiviral activity and one inhibited a cytopathic effect in a non-cytotoxic concentration range. These results highlight the druggability of the rarely explored ISG15/Ub-S2 PLpro allosteric binding site to identify new and effective antiviral compounds. Importantly, in the context of increasing PLpro mutations in the evolving new variants of SARS-CoV-2, the natural compounds we identified may also reinstate the antiviral immune response processes of the host that are down-regulated in COVID-19 infections.

After more than one and half year, the coronavirus disease COVID-19, caused by SARS-CoV-2, remains devastating with high numbers of infections and deaths 1 .

Several approved and commercialized vaccines against COVID-19 were developed worldwide in only a year. However, these vaccines are not uniformly available around the world, and consequently new SARS-CoV-2 variants have already emerged which may impact the effectiveness of the available vaccines in the future 2 . In parallel, more efforts are needed to identify and optimize alternative treatments for patients infected by SARS-CoV-2, who do not respond to or cannot tolerate vaccines 3 . Hence, research is ongoing at a rapid pace to identify effective drug candidates by applying complementary strategies. One approach, we followed recently, is the massive X-ray crystallographic screening for inhibitors of SARS-CoV-2 main protease Mpro, an essential protein in the viral replication process and hence an important drug target 4 . We identified six compounds inhibiting Mpro that showed antiviral activity and these compounds are currently approaching the step of pre-clinical investigations 4 .

The positive-sense single stranded RNA genome of coronaviruses encodes 16 nonstructural polyproteins (nsps [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The Papain-like protease (PLpro) is a domain that is part of the nsp3 gene, the largest mature SARS-CoV-2 protein 5 .

PLpro is required to recognize and cleave the motif LXGG within preprocessed polyproteins between nsp1/2, nsp2/3 and nsp3/4 into functional units for initiation, replication and transcription of the viral genome 6, 7 . Apart from the proteolytic activity, PLpro can also bind and cleave ubiquitin chains or ISG15 (interferonstimulated gene product 15) from ubiquitinated or ISGylated proteins 8 . The deubiquitinase (DUB), as well as deISGylating activities are vital for the coronaviruses to antagonize the host immune responses. It has been shown that mono-ubiquitination at the endoplasmic reticulum (ER) membranes regulate endocytosis, and vesicle trafficking and thus is important for coronavirus propagation 9 . On the other hand, ISG15 causes metabolic pathway modifications towards excessive inflammatory and autoimmune responses due to interferon system dysregulations 10, 11 . Target proteins for the coronavirus, such as IRF3 (Interferon regulatory factor 3) need to conjugate with ISG15 to be correctly phosphorylated for their entry into nucleus where they are required for downstream signalling events for e.g., via the IFN-β pathway 12 to elicit an antiviral immune response. Therefore, the cysteine protease activity, together with the deubiquitinase and deISGylating activity of PLpro undoubtedly makes this enzyme a very promising target for drug discovery investigations 20, 21 . Furthermore, the importance of PLpro as a drug target was highlighted in several recent studies that have identified novel and unexpected mutations in the PLpro domain of the nsp3 gene from the SARS-CoV-2 variants of concern (VOC), currently circulating in different parts of the world 13, 14 .

The crystal structure of SARS-CoV PLpro, in complex with Lys48-linked di-ubiquitin 15 (PDB code 5E6J), clearly evokes a mechanism of DUB action in which the LXGG residues at the C-terminal of the ubiquitin molecule bind in a cleft (Ub S1 proximal binding site) located close to the catalytic active site, allowing efficient cleavage. In addition, the recently obtained crystal structure of SARS-CoV-2 PLpro, in complex with mouse-ISG15 16 , demonstrates that the N-terminal of ISG15 interacts with PLpro at a different binding site termed as ISG15/Ub S2 distal binding site. Compared to the crystal structure of ISG15 (PDB code 5TLA), the Nterminal half of the ISG15 molecule is rotated by about 90 o and coordinates with the S2-helix, as shown in the complex structure of SARS-CoV-2 PLpro with ISG15.

These different binding events explain and highlight why SARS-CoV-2 PLpro and SARS-CoV PLpro, despite sharing 83% sequence identity show different host substrate preferences. Recently data were published showing higher affinity and specificity of SARS-CoV-2 PLpro to ISG15, whereas SARS-CoV PLpro preferentially cleaves ubiquitin chains, which may be associated to the substantial higher morbidity and mortality of SARS-CoV-2 in comparison to SARS-CoV infections 17 .

Until now several high throughput assay screening (HTS) activities, focussed on identifying potential inhibitors of PLpro using repurposing compound libraries were initiated. Unfortunately, these were not very successful in obtaining hits of compounds that could be further developed to obtain an effective antiviral drug 17 . Hence, we set out a different strategy to explore a unique library consisting of 500 natural compounds assembled and characterized by the Molecular Bank, ICCBS, Karachi, Pakistan, by structure-based drug design (https://iccs.edu/pagemol-bank). Natural compounds of the ICCBS Molecular Bank extracted from plants present characteristics such as high chemical diversity, medically relevant antitumor, anti-oxidant, anti-inflammatory and importantly antiviral action with typically milder or no side effects, in addition to lower cost of production as compared to most available drugs on the market 18 Interestingly, all three compounds YRL, HBA and HE9 bind at the same, and yet unexplored ISG15/Ub-S2 allosteric binding site of PLpro by forming specific interactions and clearly inhibit PLpro in deISGylation activity assays. None of these lead compounds are cytotoxic in cellular cytotoxicity assays, demonstrating their potential as drug molecules. Significantly, two of them exhibit antiviral activity and one inhibits cytopathic effects in the range of 60-80% in a noncytotoxic concentration range up to 100 µM in cellular assays. These three natural phenolic compounds undoubtedly provide a scaffold as antiviral drugs for further development and optimization towards the prevention and/or reduction of SARS-CoV-2 viral replication, and to reinstate and support the innate immune response of the host in parallel.

We initiated a structure-based drug discovery approach to identify potential inhibitors for PLpro by X-ray screening of 500 compounds from the ICCBS Molecular Bank. SARS-CoV-2 PLpro was expressed recombinantly in Escherichia coli, and purified to homogeneity as a monomer (see materials and methods). Wildtype enzyme crystals were obtained in a stable and reproducible condition and diffracted X-rays to a high resolution of 1.42 Å. Data collection and refinement statistics are summarized in the Supplementary Table 1. The electron density maps obtained for the wild-type enzyme allowed the elucidation of all 315 amino acid residues, the zinc ion and 529 solvent water molecules. Further, a glycerol molecule from the cryoprotectant, used for freezing crystals, could be modelled in the electron density map, as well as a phosphate and two chloride ions.

PLpro folds with a right-handed architecture consisting of thumb, palm, and fingers domains with a catalytic triad consisting of Cys111-His272-Asp286 and a N-terminal ubiquitin-like domain ( Figure 1 ). Four cysteine side chains coordinate a zinc ion, constituting a 'zinc finger motif' that is essential for structural stability and protease activity of the enzyme 29 . The overall structure of SARS-CoV-2 PLpro is similar to SARS-CoV PLpro (PDB code 2FE8) that shares a sequence identity of Crystals of SARS-CoV-2 PLpro, in complex with the three natural compounds, were obtained by co-crystallization using the vapour diffusion method in a screening approach utilizing 500 molecules from a library of natural compounds. Crystals were grown in the same condition as for the native PLpro and diffraction datasets were collected in the resolution range of 1.7-1.9 Å. Over 2,000 crystals were harvested, and multiple datasets for each compound were collected that resulted in ~2500 diffraction datasets. PLpro structures complexed with inhibitor compounds were solved using the ligand-free PLpro (PDB code 7NFV) as reference model for consistent indexing of datasets with a previously established automatic pipeline 4 (see materials and methods). Data collection and refinement statistics are summarized in Table 1 Figure 1 ) that is located about 30 Å apart to the active site residue Cys 111. The interaction between these allosteric inhibitors and PLpro are formed via hydrogen bonds, hydrophobic, and π-stacking interactions ( Figure S2A , B, C).

The natural compound 4-(2-hydroxyethyl)phenol (YRL), isolated from Lawsonia alba, is a well-known antioxidant and an anti-arrythmia agent Cleavage of polyubiquitin chains by SARS-CoV-2 PLpro is significantly enhanced when a longer ubiquitin chain is used. This demonstrates that either Ub or ISG15 molecules bind not only to the Ub-S1 binding site but also to the Ub-S2 site, facilitated by the conserved S2 helix in PLpro, being important for the enzymatic activity 34 . Superimposition of crystal structures of PLpro in complex with Lys48 linked di-ubiquitin (5E6J) with the PLpro-HE9 complex (7OFU) showed that key residues involved in ubiquitination, Lys 11 and Lys 48 in the S2-Ub binding site, are no longer available for binding either to ubiquitin or ISG15 ( Figure S4A, B) .

Hence, a clear molecular basis for the inhibition emerges from the three PLpro inhibitor complex structures, showing that PLpro-ISG15 interactions are affected upon the binding of the three phenolic natural products.

A fluorescence deubiquitinating activity assay was carried out to assess the inhibitory effect of the three compounds (HE9, YRL, and HBA), co-crystallized with the wild type SARS-CoV-2 PLpro. A catalytically inactive PLpro mutant (C111S) was used as a control with ISG15-Rhodamine as the substrate (see materials and methods). The three natural products clearly inhibited the enzymatic reaction of PLpro. In particular the two compounds, HBA and YRL significantly decreased PLpro activity by 73%, followed by HE9 inhibiting to 55% in a deISGylation assay ( Figure S6 & Table 2 ). It can be rationalized that the binding of the natural compounds at the S2 helix region is determinant and clearly disrupts the essential PLpro/ISG15 molecular interactions required for the enzymatic mechanism, as seen in the crystal structures of PLpro inhibitor complexes.

Further, we determined the efficacy of inhibition of the three compounds by in vitro IC 50 assays, which demonstrated a potential effect of all three natural products in a concentration range of 3.76 up to 6.68µM. The compound, GRL0617

inhibitor of PLpro was used as a control ( Figure 3 , Table 2 ). Antiviral activities for these natural phenolic compounds, either in crude or purified forms previously reported from several studies 35, 36 can now be rationally related to PLpro inhibition as we show in our activity assays, in addition to other target proteins such as Mpro, that are involved in the viral replication process.

Considering the observed inhibitory synergic effect, combined with the molecular regulative antiviral homeostasis function of ISG15 in the human host, we investigated the inhibitory efficacy of the compounds HE9, HBA, and YRL towards viral replication and the cytopathic effect in living cells using Vero cell line assays.

Two distinct approaches were applied, qRT-PCR reaction as previously described 4 and CellTiter-Glo assay, a luciferase reporter assay to determine the ATP level present in viable cells 37 Figure 4C ). An active compound was the one which exhibited a CPE inhibition of > 50% without compromising cell viability. We were unable to fit a sigmoidal curve to the data for HBA and YRL and values are presented in a line graph (Figure 4a ' and 4c'). Importantly, treatment of the cells with the compound HE9 reduced the viral replication and showed an ability to inhibit CPE with EC 50 = 10µM ( Figure   4C ). These results from the cellular assays are in line with the in vitro enzymatic studies using deISGlyation assays and clearly demonstrate that the compound HE9 is a potential inhibitor of PLpro, which can protect the host cells from the viral CPE.

In summary, the high resolution PLpro complex structures with phenolic natural compounds YRL, HBA and HE9 complemented by enzymatic and cellular assays, provide a molecular basis to understand the inhibitory mechanism, a route to develop effective PLpro inhibitors of ISG15 binding to PLpro and shed light on the mode of ISGylation of COVID-19 viral proteins as a new approach for preventing their interaction with human host cellular pathways. We believe that this approach to inhibit PLpro may hinder and reduce the viral ability to perform de-ISGylation in post COVID-19 viral complications, as well as providing more ISG15 within the lung tissues for the modulation of cytokine/chemokine production, to support the repair of the respiratory epithelium within COVID-19 infections 11 . 

Diffraction data from the ligand-free and complex PLpro crystals were collected at beamline P11, PETRA III / DESY, Hamburg. All datasets of ligand-free PLpro were processed using the program XDS 39 with a reference dataset to ensure consistent indexing. From a total of 64 complete datasets, the strongest were selected based on (I/σ) asymptotic greater than 20 40 . These 25 datasets were then subjected to iterative merging using CODGAS 41 An automatic data processing pipeline, hit finding, clustering 46 , PanDDA analysis 47 and refinement protocols as described previously 4 Table 1, supplementary information. All figures were prepared using PyMol 50 .

Activity assays were performed for SARS-CoV-2 PLpro native and mutant enzyme (PLpro C111S mutant) to determine the deISGylation activity effected by the three natural compounds, following previously published protocols 16 Samples deemed to be technical failures and extreme outlier were removed. 

The authors declare no competing interests.

Correspondence and requests for materials should be addressed to vasundara.srinivasan@chemie.uni-hamburg.de christian.betzel@uni-hamburg.de ( , ). The viral titer and cell viability were quantified by qRT-PCR (•) and CellTiter-Glo luminescence method (■), respectively. EC 50 -and R-squared values for viral titers are shown. EC 50 -values were calculated by fitting the data to the sigmoidal function as previously described 4 . Compounds concentrations are presented in log scale for interpolation. HE9 and HBA compounds were diluted to a stock concentration of 100 mM in DMSO, while YRL was diluted in sterile water to a 50 mM stock concentration. All compounds were stored at -20°C. Individual data points represent means ± SD from four independent replicates in two biological experiments. a'. Values were plotted in a line graph with error bars displaying standard deviation.

Cell viability was determined by CellTiter-Glo luminescence method. Individual data points represent means ± SD from three independent replicates in three biological experiments.

CPE inhibition was determined by CellTiter-Glo luminescence method. EC 50and R-squared values are shown. EC 50 -values were calculated by fitting the data to the sigmoidal function. Individual data points represent means ± SD from three independent replicates in one biological experiment. c'. Values were plotted in a line graph with error bars displaying standard deviation. 

The S2 binding ISG15 site in PLpro consisting of residues Phe 69, Glu 70, Tyr 72, His 73 and Leu 80 is conserved between SARS-CoV and SARS-CoV2.

The sequence alignment for the region corresponding to the S2 ISG15 binding site shows that the MERS-CoV differs in critical binding residues; Phe 69 in SARS-CoV-2 PLpro is replaced by a lysine residue (F69K), Tyr 72 to a leucine residue (Y72L) and His 73 to a glycine residue (H73G). Wild type PLpro (WT PLpro) at 10nM concentration represents 100% of deISGylation activity and the three natural compounds YRL, HBA and HE9 at 50 µM show clear inhibition of PLpro enzymatic activity. As experimental control, catalytically inactive PLpro mutant C111S at 10nM concentration was used. ISG15-Rh at a concentration of 100nM was used as the substrate. Measured fluorescence values were blank corrected with buffer containing substrate and were measured in triplicates over 60 min with one read per minute. Approximately 2000 crystals of PLpro co-crystallized with the library of 500 compounds were harvested for data collection. More than one dataset per compound was collected that resulted in about 2500 datasets. A total of 1469 datasets were processed with the previously established automatic pipeline 4 . Data quality indicators, resolution (left), CC 1/2 (middle) and Wilson B-factor (right) are shown. 

Emerging Pandemic Diseases: How We Got to COVID-19

SARS-CoV-2 variants, spike mutations and immune escape

Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein

Papain-Like Protease 2 (PLP2) from Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV): Expression, Purification, Characterization, and Inhibition

The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

Governance of Endocytic Trafficking and Signaling by Reversible Ubiquitylation

SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals

ISG15 in antiviral immunity and beyond

SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species

Identification of novel mutations in SARS-COV-2 isolates from Turkey

Mutational analysis and assessment of its impact on proteins of SARS-CoV-2 genomes from India

Recognition of Lys48-Linked Di-ubiquitin and Deubiquitinating Activities of the SARS Coronavirus Papain-like Protease

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2

Natural products as sources of new drugs over the last 25 years

Hepatitis C virus and natural compounds: a new antiviral approach? Viruses

Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)

A review on potential of natural products in the management of COVID-19

Antiviral Activity of Metabolites from Peruvian Plants against SARS-CoV-2: An In Silico Approach

Inhibitory Effects of Resveratrol on the Epstein-Barr Virus Lytic Cycle

Resveratrol inhibits Epstein Barr Virus lytic cycle in Burkitt's lymphoma cells by affecting multiple molecular targets

Polyphenols Epigallocatechin Gallate and Resveratrol, and Polyphenol-Functionalized Nanoparticles Prevent Enterovirus Infection through Clustering and Stabilization of the Viruses

Resveratrol as a Novel Anti-Herpes Simplex Virus Nutraceutical Agent: An Overview

Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression

Polyphenols Have a Role Against Coronavirus Infection? An Overview of in vitro Evidence

A human RNA viral cysteine proteinase that depends upon a unique Zn2+-binding finger connecting the two domains of a papain-like fold

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery

Large-scale prediction of binding affinity in protein-small ligand complexes: the PRODIGY-LIG web server

EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro

Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design. bioRxiv

EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro

Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library

Protein production by auto-induction in high density shaking cultures

Quantifying instrument errors in macromolecular X-ray data sets

MeshAndCollect: an automated multi-crystal datacollection workflow for synchrotron macromolecular crystallography beamlines

How good are my data and what is the resolution?

Phaser crystallographic software

Current developments in Coot for macromolecular model building of Electron Cryo-microscopy and Crystallographic Data

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Pre-clustering data sets using cluster4x improves the signal-tonoise ratio of high-throughput crystallography drug-screening analysis

A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density

REFMAC5 for the refinement of macromolecular crystal structures

Use of knowledge-based restraints in phenix.refine to improve macromolecular refinement at low resolution

Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design

SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Phenolic Compounds and Flavonoids as Plant Growth Regulators from Fruit and Leaf of Vitex rotundifolia

National Institute of, S. & Technology. NIST chemistry webbook

Constituents of Schisandra verruculosa. and Their Cytotoxic Effect on Human Cancer Cell Lines

Deciphering key features in protein structures with the new ENDscript server

Supplementary Materials for SARS-CoV-2 papain-like protease PLpro in complex with natural compounds reveal allosteric sites for antiviral drug design

Hina Andaleeb(1,18), Najeeb Ullah(1,18)

Winfried Hinrichs(13)

Laboratory for Structural Biology of Infection and Inflammation, Build. 22a, c/o DESY

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)

Chemistry and Biology of Proteins (CIPKEBIP)

Correspondence to: vasundara.srinivasan@chemie.uni-hamburg.de, christian.betzel@uni-hamburg.de This PDF file includes: loop in purple, the ISG15 binding S1 site in dark red and the ISG15 S2 allosteric binding site overlapping with the inhibitor binding site is shown in light blue

Figs. S1 to S8 Tables S1 to S2 .